Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.


TSX:CRDL - Post by User

Comment by Mapleleaf57on Jan 03, 2021 11:36am
118 Views
Post# 32211412

RE:RE:RE:CRDL...1 of 10 Cannabis Companies to be Watching in 2021....

RE:RE:RE:CRDL...1 of 10 Cannabis Companies to be Watching in 2021....

Jimmy Mengel is out with a new marijuana stock ad for us, teasing the “next king” of the sector as he looks for more winners… and, of course, he’d like you to subscribe to his newsletter to learn what this next winner might be (actually, he’s pitching this as “you buy my $99 report, nonrefundable, and I’ll give you a free one-year subscription to The Crow’s Nest, after which that will autorenew at $129/year, but whatever).

 
<< Previous
Bullboard Posts
Next >>